A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Trial Profile

A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs Vadadustat (Primary)
  • Indications Anaemia; Infections; Pelvic inflammatory disorders
  • Focus Adverse reactions
  • Sponsors Akebia Therapeutics
  • Most Recent Events

    • 10 Nov 2014 Results published in an Akebia Therapeutics media release.
    • 19 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top